Filing Details
- Accession Number:
- 0001610717-24-000491
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-09-20 17:23:59
- Reporting Period:
- 2024-09-18
- Accepted Time:
- 2024-09-20 17:23:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1966494 | Cargo Therapeutics Inc. | CRGX | Biological Products, (No Disgnostic Substances) (2836) | 844080422 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1999930 | Anup Radhakrishnan | C/O Cargo Therapeutics, Inc. 835 Industrial Road, Suite 400 San Carlos CA 94070 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-09-18 | 1,600 | $5.03 | 8,046 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-09-18 | 1,600 | $25.28 | 6,446 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-09-18 | 1,600 | $0.00 | 1,600 | $5.03 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 53,180 | 2033-04-20 | No | 4 | M | Direct |
Footnotes
- The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 28, 2024.
- This transaction was executed in multiple trades in prices ranging from $25.25 to $25.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- 25% of the shares subject to the option vest on the first anniversary measured from February 9, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Billionaire Hedge Funds
